RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00034925.xml
Hamostaseologie 2017; 37(04): 238
DOI: 10.1055/s-0037-1619836
DOI: 10.1055/s-0037-1619836
Editorial
Non-factor replacement therapies in hemophilia
Hot TopicWeitere Informationen
Publikationsverlauf
received:
21. September 2017
accepted:
21. September 2017
Publikationsdatum:
28. Dezember 2017 (online)
-
References
- 1 Ragni MV. Targeting antithrombin to treat hemophilia. N Engl J Med 2015; 373: 389-391.
- 2 Shima M, Hanabusa H, Taki M. et al. Factor VIIImimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374: 2044-2053.
- 3 Klamroth R. A new era of treatment for patients with haemophilia A?. Hämostaseologie 2017; 37: 216-218.
- 4 Scharf RE. Hot topic: Alloantibodies to therapeutic FVIII and the use of emicizumab in hemophilia A. Hämostaseologie 2016; 36: 195-198.
- 5 Tiede A. Thrombotic risks of non-factor replacement therapies in hemophilia. Hämostaseologie 2017; 37: 307-310.
- 6 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809-818.
- 7 Pasi KJ, Rangarajan S, Georgiev P. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377: 819-828.